Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses

BackgroundThere is a greater risk of complications from severe COVID-19 in immunocompromised patients with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs), as well as a diminished vaccine response.MethodsIn this exploratory, observational study, we recruited 28 pati...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ryan Curtin, Yogambigai Velmurugu, Fatoumatta Dibba, Yuan Hao, Samantha Nyovanie, Andrea Lopez, David Mieles, Courtney Ng, Katherine Perdomo, Nicole Scott, James B. Lewin, Robin L. Avila, Jen Smrtka, Yury Patskovsky, Jonathan Howard, Gregg J. Silverman, Michelle Krogsgaard
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2025-11-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	multiple sclerosis (MS) T cell B cell SARS-CoV-2 COVID-19 natalizumab (Tysabri)
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1568157/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!